Type 1 diabetes

Diabetes groups opposed to pharmacist substitution of insulin

Diabetes groups have joined forces against moves to allow pharmacists to substitute biosimilar insulins, saying it has the potential to seriously disrupt diabetes management. The joint statement from the Australian Diabetes Education Association, the Australian Diabetes Society and Diabetes Australia is in response to a PBAC recommendation to list the biosimilar insulin glargine product Basaglar on ...

Already a member?

Login to keep reading.

© 2021 the limbic